PE20120602A1 - ATROPISOMEROS DE 2-[(6-AMINO-9H-PURIN-9-IL)METIL]-5-METIL-3-o-TOLILQUINAZOLIN-4(3H)-ONA - Google Patents
ATROPISOMEROS DE 2-[(6-AMINO-9H-PURIN-9-IL)METIL]-5-METIL-3-o-TOLILQUINAZOLIN-4(3H)-ONAInfo
- Publication number
- PE20120602A1 PE20120602A1 PE2011001710A PE2011001710A PE20120602A1 PE 20120602 A1 PE20120602 A1 PE 20120602A1 PE 2011001710 A PE2011001710 A PE 2011001710A PE 2011001710 A PE2011001710 A PE 2011001710A PE 20120602 A1 PE20120602 A1 PE 20120602A1
- Authority
- PE
- Peru
- Prior art keywords
- methyl
- purin
- amino
- atropisomer
- tolilquinazolin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Abstract
SE REFIERE A UN ATROPISOMERO OPTICAMENTE ACTIVO DEL COMPUESTO 2-((6-AMINO-9H-PURIN-9-IL)METIL)-5-METIL-3-O-TOLILQUINAZOLIN-4(3H)-ONA QUE SE OBTIENE POR SEPARACION DE UNA MEZCLA RACEMICA, EL CUAL COMPRENDE EL ATROPISOMERO 1(R) Y EL ATROPISOMERO 1(S). TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO INHIBE LAS ISOFORMAS DE LA FOSFATIDILINOSITOL-3,4,5-TRIFOSFATO QUINASA ? (PI3K?) SIENDO UTIL EN EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS Y CANCER
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16298009P | 2009-03-24 | 2009-03-24 | |
US23155009P | 2009-08-05 | 2009-08-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20120602A1 true PE20120602A1 (es) | 2012-05-21 |
Family
ID=42289320
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2011001710A PE20120602A1 (es) | 2009-03-24 | 2010-03-24 | ATROPISOMEROS DE 2-[(6-AMINO-9H-PURIN-9-IL)METIL]-5-METIL-3-o-TOLILQUINAZOLIN-4(3H)-ONA |
Country Status (19)
Country | Link |
---|---|
US (1) | US8440677B2 (es) |
EP (1) | EP2411391A1 (es) |
JP (1) | JP2012521994A (es) |
KR (1) | KR20120002995A (es) |
CN (1) | CN102439012A (es) |
AP (1) | AP2011005943A0 (es) |
AU (1) | AU2010229968A1 (es) |
BR (1) | BRPI1012333A2 (es) |
CA (1) | CA2756347A1 (es) |
CL (1) | CL2011002359A1 (es) |
CO (1) | CO6450655A2 (es) |
EA (1) | EA019499B1 (es) |
EC (1) | ECSP11011412A (es) |
IL (1) | IL215251A0 (es) |
MX (1) | MX2011009955A (es) |
NZ (1) | NZ595307A (es) |
PE (1) | PE20120602A1 (es) |
SG (1) | SG174529A1 (es) |
WO (1) | WO2010111432A1 (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
WO2005016348A1 (en) * | 2003-08-14 | 2005-02-24 | Icos Corporation | Method of inhibiting immune responses stimulated by an endogenous factor |
AU2005245875C1 (en) | 2004-05-13 | 2017-08-31 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
CN102271683B (zh) | 2008-11-13 | 2014-07-09 | 吉里德卡利斯托加公司 | 恶性血液病的治疗 |
US9492449B2 (en) | 2008-11-13 | 2016-11-15 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
EA019499B1 (ru) | 2009-03-24 | 2014-04-30 | ГИЛИЭД КАЛИСТОГА ЭлЭлСи | Производные атропоизомеров 2-пуринил-3-толилхиназолинона и способы применения |
EP2421536B1 (en) * | 2009-04-20 | 2015-08-26 | Gilead Calistoga LLC | Methods of treatment for solid tumors |
JP5718323B2 (ja) * | 2009-05-29 | 2015-05-13 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 放射標識されたpde10阻害剤 |
WO2011011550A1 (en) * | 2009-07-21 | 2011-01-27 | Calistoga Pharmaceuticals Inc. | Treatment of liver disorders with pi3k inhibitors |
GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
UY33337A (es) | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
EP2518070A1 (en) * | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
EP2518071A1 (en) * | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Imidazopyridine derivatives as PI3K inhibitors |
PT2790705T (pt) | 2011-12-15 | 2018-01-24 | Novartis Ag | Utilização de inibidores da atividade ou função de pi3k |
WO2013134288A1 (en) | 2012-03-05 | 2013-09-12 | Gilead Calistoga Llc | Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one |
LT2834244T (lt) | 2012-03-13 | 2016-11-10 | Respivert Limited | Kristalinės pi3 kinazės slopikliai |
PL2870157T3 (pl) | 2012-07-04 | 2018-01-31 | Rhizen Pharmaceuticals S A | Selektywne inhibitory pi3k delta |
WO2014015523A1 (en) * | 2012-07-27 | 2014-01-30 | Hutchison Medipharma Limited | Novel heteroaryl and heterocycle compounds, compositions and methods |
WO2014060431A1 (en) * | 2012-10-16 | 2014-04-24 | Almirall, S.A. | Pyrrolotriazinone derivatives as pi3k inhibitors |
JP2015533181A (ja) * | 2012-10-16 | 2015-11-19 | アルミラル・ソシエダッド・アノニマAlmirall, S.A. | Pi3k阻害剤としてのピロロトリアジノン誘導体 |
KR20150079745A (ko) * | 2012-11-08 | 2015-07-08 | 리젠 파마슈티컬스 소시에떼 아노님 | Pde4 억제제 및 pi3 델타 또는 이중 pi3 델타-감마 키나아제 억제제를 함유하는 약제학적 조성물 |
US9227977B2 (en) | 2013-03-15 | 2016-01-05 | Respivert Ltd. | Phosphoinositide 3-kinase inhibitors |
TW201522341A (zh) * | 2013-03-15 | 2015-06-16 | Respivert Ltd | 化合物 |
UY35675A (es) | 2013-07-24 | 2015-02-27 | Novartis Ag | Derivados sustituidos de quinazolin-4-ona |
CN104513235B (zh) * | 2013-09-02 | 2017-12-05 | 广东东阳光药业有限公司 | 取代的氨基嘧啶类化合物及其使用方法和用途 |
KR20160060100A (ko) | 2013-09-22 | 2016-05-27 | 칼리토르 사이언시즈, 엘엘씨 | 치환된 아미노피리미딘 화합물 및 이용 방법 |
ES2752552T3 (es) | 2013-12-20 | 2020-04-06 | Gilead Calistoga Llc | Métodos de proceso para inhibidores de fosfatidilinositol 3-quinasa |
WO2015095605A1 (en) | 2013-12-20 | 2015-06-25 | Gilead Calistoga Llc | Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one |
DK3149000T3 (da) | 2014-05-27 | 2021-08-30 | Rhizen Pharmaceuticals S A | Krystallinsk tosylatsalt af en pi3k-delta-selektiv inhibitor til anvendelse i farmaceutiske formuleringer |
MD20160137A2 (ro) * | 2014-05-27 | 2017-05-31 | Almirall S.A. | Utilizare medicală |
US11021467B2 (en) | 2014-06-13 | 2021-06-01 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
AU2015283671B2 (en) | 2014-07-04 | 2018-07-05 | Lupin Limited | Quinolizinone derivatives as Pl3K inhibitors |
US10550124B2 (en) * | 2015-08-13 | 2020-02-04 | San Diego State University Foundation | Atropisomerism for increased kinase inhibitor selectivity |
WO2017122000A1 (en) | 2016-01-11 | 2017-07-20 | Queen Mary University Of London | Inhibitors of pi3k p-delta 110 for use in delivery of viruses in the treatment of cancer |
US10836759B2 (en) | 2016-06-22 | 2020-11-17 | The University Of North Carolina At Chapel Hill | Thiazole derivatives useful as mutant IDH1 inhibitors for treating cancer |
US10016425B2 (en) | 2016-11-03 | 2018-07-10 | King Saud University | Anti-ulcerative colitis compound |
US20220112217A1 (en) * | 2018-08-21 | 2022-04-14 | Medshine Discovery Inc. | Pyrazolopyrimidine derivative and use thereof as pi3k inhibitor |
US20220009920A1 (en) | 2020-04-10 | 2022-01-13 | Gb005, Inc. | Kinase inhibitors |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1249281B (es) | 1963-05-18 | |||
US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
DE2027645A1 (de) | 1970-06-05 | 1971-12-09 | Byk Gulden Lomberg Chemische Fa bnk GmbH, 7750 Konstanz | Piperazinylalkyl chinazolon (4) den vate, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel |
NL7204972A (es) | 1971-04-21 | 1972-10-24 | ||
US3897432A (en) | 1971-04-21 | 1975-07-29 | Merck & Co Inc | Substituted benzimidazole derivatives |
CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
DE2644265C2 (de) | 1976-09-30 | 1983-02-10 | Bayer Ag, 5090 Leverkusen | Chinazoline |
US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
US4183931A (en) | 1977-09-08 | 1980-01-15 | Research Corporation | 2-Ketoalkyl-4(3H)-quinazolinones |
US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
DE2812635A1 (de) | 1978-03-22 | 1979-09-27 | Bayer Ag | Heterocyclische verbindungen |
JPS55118917A (en) | 1979-03-06 | 1980-09-12 | Mitsubishi Electric Corp | Production of quinazolone ring-containing epoxy resin |
JPS55118918A (en) | 1979-03-06 | 1980-09-12 | Mitsubishi Electric Corp | Production of quinazolone ring-containing epoxy resin |
US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
JPS6017375B2 (ja) | 1979-06-20 | 1985-05-02 | 三菱電機株式会社 | ポリアミド樹脂の製造方法 |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
USRE35862E (en) | 1986-08-18 | 1998-07-28 | Emisphere Technologies, Inc. | Delivery systems for pharmacological agents encapsulated with proteinoids |
EP0318512B1 (en) | 1986-08-18 | 1998-06-17 | Emisphere Technologies, Inc. | Delivery systems for pharmacological agents |
US6696250B1 (en) | 1986-12-03 | 2004-02-24 | Competitive Technologies, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
EP0364598A4 (en) | 1988-03-02 | 1992-01-15 | Yoshitomi Pharmaceutical Industries, Ltd. | 3,4-dihydrothieno 2,3-d¨pyrimidine compounds and pharmaceutical application thereof |
US5225347A (en) | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Therapeutic ribozyme compositions and expression vectors |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
FR2675803B1 (fr) | 1991-04-25 | 1996-09-06 | Genset Sa | Oligonucleotides fermes, antisens et sens et leurs applications. |
ES2084940T3 (es) | 1991-06-18 | 1996-05-16 | American Home Prod | Uso de la rapamicina para el tratamiento de la leucemia/linfoma de las celulas t adultas. |
ATE156158T1 (de) | 1992-04-14 | 1997-08-15 | Cornell Res Foundation Inc | Makromoleküle auf basis von dendritischen polymeren und verfahren zur herstellung |
US5658780A (en) | 1992-12-07 | 1997-08-19 | Ribozyme Pharmaceuticals, Inc. | Rel a targeted ribozymes |
GB9301000D0 (en) | 1993-01-20 | 1993-03-10 | Glaxo Group Ltd | Chemical compounds |
US5378725A (en) | 1993-07-19 | 1995-01-03 | The Arizona Board Of Regents | Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof |
GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
FI951367A (fi) | 1994-03-28 | 1995-09-29 | Japan Energy Corp | Puriinijohdannaiset ja tulehdustautien tukahduttajat (suppressantit) |
US5480906A (en) | 1994-07-01 | 1996-01-02 | Eli Lilly And Company | Stereochemical Wortmannin derivatives |
AU712835B2 (en) | 1994-08-12 | 1999-11-18 | Pro-Neuron, Inc. | Methods for treating sepsis or inflammatory diseases with oxypurine nucleosides |
US5561138A (en) | 1994-12-13 | 1996-10-01 | American Home Products Corporation | Method of treating anemia |
JP3233802B2 (ja) | 1994-12-15 | 2001-12-04 | 関西電力株式会社 | 燃焼排ガス中の炭酸ガスと窒素酸化物を除去する方法 |
US6043062A (en) | 1995-02-17 | 2000-03-28 | The Regents Of The University Of California | Constitutively active phosphatidylinositol 3-kinase and uses thereof |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US5948664A (en) | 1996-02-29 | 1999-09-07 | The Regents Of The University Of California | PI 3-kinase polypeptides |
JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
BR9709085A (pt) | 1996-05-15 | 1999-08-03 | Pfizer | Novas 2,3-dissubstituído-4(3H)-quinazolinonas |
GB9611460D0 (en) | 1996-06-01 | 1996-08-07 | Ludwig Inst Cancer Res | Novel lipid kinase |
US5858753A (en) | 1996-11-25 | 1999-01-12 | Icos Corporation | Lipid kinase |
DK0958296T3 (da) | 1996-12-31 | 2003-08-18 | Reddys Lab Ltd Dr | Heterocykliske forbindelser, fremgangsmåde til deres fremstilling og farmaceutiske præparater, der indeholder dem, og deres anvendelse i behandlingen af diabetes og beslægtede sygdomme |
GB9702701D0 (en) | 1997-02-01 | 1997-04-02 | Univ Newcastle Ventures Ltd | Quinazolinone compounds |
DK0968194T3 (da) | 1997-02-28 | 2004-08-16 | Pfizer Prod Inc | Atropisomerer af 3-aryl-4(3H)-quinazolinoner og deres anvendelse som AMPA-receptor-antagonister |
DE69823339T2 (de) * | 1997-02-28 | 2005-05-12 | Pfizer Products Inc., Groton | Atropisomere 3-heteroaryl-4(3h)-chinazolinone zur behandlung von neurodegenerativen und cns-trauma zuständen |
ATE303997T1 (de) | 1997-06-09 | 2005-09-15 | Pfizer Prod Inc | Chinazolin-4-on ampa antagonisten |
WO1999001139A1 (en) | 1997-07-03 | 1999-01-14 | Thomas Jefferson University | An improved method for design and selection of efficacious antisense oligonucleotides |
IL125950A0 (en) | 1997-09-05 | 1999-04-11 | Pfizer Prod Inc | Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy |
JP2002500188A (ja) | 1998-01-08 | 2002-01-08 | ザ・ユニバーシティ・オブ・バージニア・パテント・ファウンデーション | A2aアデノシンレセプター作動因子 |
EP1073643B1 (en) | 1998-04-23 | 2004-12-29 | Dr. Reddy's Laboratories Ltd. | New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
US6048970A (en) | 1998-05-22 | 2000-04-11 | Incyte Pharmaceuticals, Inc. | Prostate growth-associated membrane proteins |
US6100090A (en) | 1999-06-25 | 2000-08-08 | Isis Pharmaceuticals Inc. | Antisense inhibition of PI3K p85 expression |
US6046049A (en) | 1999-07-19 | 2000-04-04 | Isis Pharmaceuticals Inc. | Antisense modulation of PI3 kinase p110 delta expression |
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
ATE502941T1 (de) | 2000-04-25 | 2011-04-15 | Icos Corp | Hemmer der menschlichen phosphatidyl-inositol-3- kinase delta |
EP1939203B1 (en) | 2000-04-25 | 2014-11-19 | ICOS Corporation | Inhibitors of human phosphatidyl-inositol 3-kinase delta isoform |
US20040092561A1 (en) | 2002-11-07 | 2004-05-13 | Thomas Ruckle | Azolidinone-vinyl fused -benzene derivatives |
MXPA05000453A (es) | 2002-07-10 | 2005-03-23 | Applied Research Systems | Derivados de benceno fusionados a azolidinona-vinilo. |
GB0217777D0 (en) | 2002-07-31 | 2002-09-11 | Novartis Ag | Organic compounds |
US20040023390A1 (en) | 2002-08-05 | 2004-02-05 | Davidson Beverly L. | SiRNA-mediated gene silencing with viral vectors |
CA2400254A1 (en) | 2002-09-19 | 2004-03-19 | University Health Network | Compositions and methods for treating heart disease |
PL226562B1 (pl) | 2002-09-30 | 2017-08-31 | Bayer Pharmaceuticals Corp | Skondensowane pochodne azolopirymidyn, leki zawierające takie pochodne oraz ich zastosowanie |
JP2006510661A (ja) | 2002-12-06 | 2006-03-30 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | Pi3kの阻害剤としてのベンズオキサジン−3−オン類及びその誘導体 |
WO2004056820A1 (en) | 2002-12-20 | 2004-07-08 | Warner-Lambert Company Llc | Benzoxazines and derivatives thereof as inhibitors of pi3ks |
WO2004089925A1 (en) | 2003-04-03 | 2004-10-21 | Semafore Pharmaceuticals, Inc. | Pi-3 kinase inhibitor prodrugs |
JP2006526605A (ja) | 2003-06-05 | 2006-11-24 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | 治療剤としての3−置換インドール類及びそれらの誘導体 |
CA2527934A1 (en) | 2003-06-05 | 2004-12-16 | Warner-Lambert Company Llc | Tetrazol benzofurancarboxamides with p13k activity as therapeutic agents |
US20040259926A1 (en) | 2003-06-05 | 2004-12-23 | Bruendl Michelle M. | 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents |
WO2004108713A1 (en) | 2003-06-05 | 2004-12-16 | Warner-Lambert Company Llc | Cycloalkyl and heterocycloalkyl substituted benzothiophenes as therapeutic agents |
BRPI0411092A (pt) | 2003-06-05 | 2006-07-18 | Warner Lambert Co | benzo[b]tiofenos substituìdos com 3-arilsulfanila e com 3-heteroarilsulfanila como agentes terapêuticos |
JP2006526610A (ja) | 2003-06-05 | 2006-11-24 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | 療法薬としてのシクロアルキルスルファニル置換ベンゾ[b]チオフェン |
US20050054614A1 (en) | 2003-08-14 | 2005-03-10 | Diacovo Thomas G. | Methods of inhibiting leukocyte accumulation |
WO2005016348A1 (en) | 2003-08-14 | 2005-02-24 | Icos Corporation | Method of inhibiting immune responses stimulated by an endogenous factor |
WO2005067901A2 (en) | 2004-01-08 | 2005-07-28 | Michigan State University | Methods for treating and preventing hypertension and hypertension-related disorders |
AU2005245875C1 (en) * | 2004-05-13 | 2017-08-31 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
CA2730540A1 (en) | 2004-05-13 | 2005-12-01 | Vanderbilt University | Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis |
JP2008500338A (ja) * | 2004-05-25 | 2008-01-10 | イコス・コーポレイション | 造血細胞の異常増殖を治療及び/又は予防する方法 |
EP1750715A1 (en) * | 2004-06-04 | 2007-02-14 | Icos Corporation | Methods for treating mast cell disorders |
EP1885356A2 (en) | 2005-02-17 | 2008-02-13 | Icos Corporation | Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation |
WO2007076085A2 (en) | 2005-12-22 | 2007-07-05 | Prolexys Pharmaceuticals, Inc . | Fused pyrimidones and thiopyrimidones, and uses thereof |
JP5313909B2 (ja) | 2006-11-13 | 2013-10-09 | アイコス コーポレイション | 炎症性疾患および癌の処置のためのチエノピリミジノン |
GB2467670B (en) | 2007-10-04 | 2012-08-01 | Intellikine Inc | Chemical entities and therapeutic uses thereof |
WO2009058361A1 (en) | 2007-10-31 | 2009-05-07 | Dynavax Technologies Corp. | Inhibition of type i ifn production |
KR101897881B1 (ko) | 2008-01-04 | 2018-09-12 | 인텔리카인, 엘엘씨 | 특정 화학 물질, 조성물 및 방법 |
CN102271683B (zh) | 2008-11-13 | 2014-07-09 | 吉里德卡利斯托加公司 | 恶性血液病的治疗 |
AU2009322187B2 (en) | 2008-12-04 | 2015-02-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of CNS disorders |
EA019499B1 (ru) | 2009-03-24 | 2014-04-30 | ГИЛИЭД КАЛИСТОГА ЭлЭлСи | Производные атропоизомеров 2-пуринил-3-толилхиназолинона и способы применения |
EP2421536B1 (en) | 2009-04-20 | 2015-08-26 | Gilead Calistoga LLC | Methods of treatment for solid tumors |
WO2011011550A1 (en) * | 2009-07-21 | 2011-01-27 | Calistoga Pharmaceuticals Inc. | Treatment of liver disorders with pi3k inhibitors |
CA2800913C (en) | 2010-06-03 | 2019-07-23 | Pharmacyclics, Inc. | The use of inhibitors of bruton's tyrosine kinase (btk) |
-
2010
- 2010-03-24 EA EA201171160A patent/EA019499B1/ru not_active IP Right Cessation
- 2010-03-24 EP EP10722454A patent/EP2411391A1/en not_active Withdrawn
- 2010-03-24 KR KR1020117024913A patent/KR20120002995A/ko not_active Application Discontinuation
- 2010-03-24 PE PE2011001710A patent/PE20120602A1/es not_active Application Discontinuation
- 2010-03-24 WO PCT/US2010/028554 patent/WO2010111432A1/en active Application Filing
- 2010-03-24 BR BRPI1012333A patent/BRPI1012333A2/pt not_active IP Right Cessation
- 2010-03-24 US US12/731,089 patent/US8440677B2/en not_active Expired - Fee Related
- 2010-03-24 AU AU2010229968A patent/AU2010229968A1/en not_active Abandoned
- 2010-03-24 CN CN2010800226099A patent/CN102439012A/zh active Pending
- 2010-03-24 JP JP2012502219A patent/JP2012521994A/ja active Pending
- 2010-03-24 CA CA2756347A patent/CA2756347A1/en not_active Abandoned
- 2010-03-24 SG SG2011068822A patent/SG174529A1/en unknown
- 2010-03-24 AP AP2011005943A patent/AP2011005943A0/xx unknown
- 2010-03-24 MX MX2011009955A patent/MX2011009955A/es active IP Right Grant
- 2010-03-24 NZ NZ595307A patent/NZ595307A/xx not_active IP Right Cessation
-
2011
- 2011-09-20 IL IL215251A patent/IL215251A0/en unknown
- 2011-09-23 CL CL2011002359A patent/CL2011002359A1/es unknown
- 2011-10-20 CO CO11140750A patent/CO6450655A2/es not_active Application Discontinuation
- 2011-10-21 EC ECSP11011412 patent/ECSP11011412A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CO6450655A2 (es) | 2012-05-31 |
AU2010229968A1 (en) | 2011-10-13 |
JP2012521994A (ja) | 2012-09-20 |
NZ595307A (en) | 2013-11-29 |
CN102439012A (zh) | 2012-05-02 |
WO2010111432A1 (en) | 2010-09-30 |
BRPI1012333A2 (pt) | 2016-03-29 |
IL215251A0 (en) | 2011-12-29 |
EA201171160A1 (ru) | 2012-04-30 |
CL2011002359A1 (es) | 2012-04-09 |
AP2011005943A0 (en) | 2011-10-31 |
SG174529A1 (en) | 2011-10-28 |
EA019499B1 (ru) | 2014-04-30 |
ECSP11011412A (es) | 2012-03-30 |
KR20120002995A (ko) | 2012-01-09 |
MX2011009955A (es) | 2011-11-18 |
EP2411391A1 (en) | 2012-02-01 |
CA2756347A1 (en) | 2010-09-30 |
US8440677B2 (en) | 2013-05-14 |
US20100249155A1 (en) | 2010-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20120602A1 (es) | ATROPISOMEROS DE 2-[(6-AMINO-9H-PURIN-9-IL)METIL]-5-METIL-3-o-TOLILQUINAZOLIN-4(3H)-ONA | |
CY1119596T1 (el) | Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης | |
CL2011002115A1 (es) | Compuestos derivados de 5-fenil-1h-piridin-2-ona y 5-fenil-pirazin-2-ona, inhibidores de la tirosina-quinasa de bruton (btk); proceso de preparación de los compuestos, compuesto intermediario, composición farmacéutica y uso en el tratamiento de enfermedades inflamatorias y/o autoinmunes. | |
CO6541569A2 (es) | Inhibidores de n1-pirazoloespirocetona acetil-coa carboxilasa | |
TN2015000084A1 (fr) | Pyridinones bicycliques nouvelles | |
CR9875A (es) | Inhibidores de dipeptidilo peptidasa para tratar diabetes | |
CR11757A (es) | Compuestos de triazina como inhibidores mtor y quinasa pi3 | |
SV2011003855A (es) | Heteroarilos sustituidos | |
BR112015021888A8 (pt) | inibidores de dna-pk, seus usos e composição farmacêutica | |
EA201100358A1 (ru) | Дабигатран для чрескожной хирургической катетеризации сердца | |
CU23874B1 (es) | 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y su uso | |
CR20140397A (es) | Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks | |
UY30500A1 (es) | Compuestos de azabencimidazolilo | |
PE20121617A1 (es) | Derivados de oxazina como inhibidores de bace | |
CO6382125A2 (es) | Inhibidores de proteína quinasa | |
MA37405A1 (fr) | Composés hétérocyclyle | |
UY32793A (es) | Compuestos inhibidores de los virus flaviviridae, composición farmacéutica que los contiene y sus usos | |
CR20120289A (es) | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol | |
EA200800726A1 (ru) | Введение ингибиторов дипептидилпептидазы | |
GT201000182A (es) | Regimen de dosificacion asociado con ésteres de paliperidona inyectables de acción prolongada | |
UY31676A1 (es) | "derivados de 3-metil-imidiazo-[1,2-b]-piridazina" | |
EA201100138A1 (ru) | 4-феноксиметилпиперидины в качестве модуляторов активности gpr119 | |
UY32848A (es) | Compuestos heterocíclicos de oxima | |
EA201390198A1 (ru) | Гетероциклическое соединение | |
EA201400976A1 (ru) | Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |